scholarly journals The use of oral and enteral tube‐fed arginine supplementation in pressure injury care: A systematic review and meta‐analysis

Nursing Open ◽  
2021 ◽  
Author(s):  
Sahar Cheshmeh ◽  
Niloofar Hojati ◽  
Arman Mohammadi ◽  
Negin Rahmani ◽  
Shima Moradi ◽  
...  
2020 ◽  
Vol 7 (2) ◽  
pp. 61-66
Author(s):  
Meysam Zarezadeh ◽  
Mohammad Reza Emami ◽  
Hamed Kord-Varkane ◽  
Seyed Mohammad Mousavi ◽  
Hamed Alizadeh ◽  
...  

2019 ◽  
Vol 122 (9) ◽  
pp. 1021-1032
Author(s):  
Amir Hadi ◽  
Arman Arab ◽  
Sajjad Moradi ◽  
Ana Pantovic ◽  
Cain C. T. Clark ◽  
...  

AbstractA number of clinical trials have examined the effect of l-arginine on lipid profile in recent years; however, the results remain equivocal. Therefore, the present study aims to summarise and quantitatively examine the available evidence on the effectiveness l-arginine supplementation on lipid parameters using a systematic review and meta-analytic approach. Online databases including PubMed, Scopus, ISI Web of Science, Cochrane Library and Google Scholar were searched up to April 2019 for randomised controlled trials that examined the effect of l-arginine supplementation on lipid profile in adults. Treatment effects were expressed as weighted mean difference (WMD) and the corresponding standard error in concentrations of serum lipids. To estimate the overall effect of l-arginine supplementation, we used the random-effects model. In total, twelve studies were included in the systematic review. The meta-analysis revealed that l-arginine supplementation did not significantly change the concentrations of total cholesterol (WMD: –5·03 mg/dl; 95 % CI –10·78, 0·73; P = 0·08; inconsistency index (I2) = 39·0 %), LDL (WMD: –0·47 mg/dl; 95 % CI –3·61, 2·66; P = 0·76; I2 = 0·0 %), or HDL (WMD: 0·57 mg/dl; 95 % CI –1·28, 2·43; P = 0·54; I2 = 68·4 %). A significant reduction was observed only in serum TAG levels (WMD: –7·04 mg/dl; 95 % CI –11·42, –2·67; P < 0·001; I2 = 0·0 %). This meta-analysis concludes that l-arginine supplementation can significantly reduce blood TAG levels; however, there is insufficient evidence to support its hypocholesterolaemic effects. To draw straightforward conclusions regarding generalised recommendations for l-arginine supplementation for improving lipid profile, there is a need for more well-controlled trials targeting exclusively patients with dyslipidaemia.


2020 ◽  
Author(s):  
Xiu Mei Tang ◽  
Duan Wang ◽  
Ying Liu ◽  
Jia Li Chen ◽  
Pei Fang Li ◽  
...  

Abstract BackgroundWe performed an updated systematic review and meta-analysis to compare the outcomes of CHA and UCHA in patients with FNFs.MethodsWe searched 6 English databases (Cochrane Library, ScienceDirect, PubMed, Embase, Medline, and Web of Science) and 4 Chinese databases (CNKI, VIP, Wang Fang, and Sino Med) in July 2020. The quality of each study was assessed according to the Cochrane handbook of systematic reviews. Data were pooled as risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (95% CIs). We used the random-effects model despite the heterogeneity among the studies. Data regarding baseline characteristics, hip function, complications both prosthetic-related and common, and operative outcomes are reported. ResultsA total of 24 RCTs based on 22 trials involving 3119 patients (CHA, 1575; UCHA, 1544) were included. Patients in CHA group show better hip function with HHS within 6 weeks (WMD=9.097, 95% CI, 3.034-15.161; P<0.003), 3 months (WMD=3.347, 95% CI, 1.478-5.216; P<0.001), 12 months (WMD=2.183, 95% CI, 0.161-4.205; P=0.034). The pooled results show that CHA had lower rates of refracture (RR=0.227, 95% CI, 0.135-0.381; P<0.0001), subsidence or loosening (RR=0.295, 95% CI, 0.112,0.778; P<0.014) and revision (RR=0.468, 95% CI, 0.279-0.786; P=0.004). Furthermore, CHA group tend to have lower pain(VAS score) (WMD=-0.568, 95% CI, -0.897 to -0.239; P=0.001), lower rate of pressure injury(RR=0.432, 95% CI, 0.221-0.846; P=0.014) and mortality at 1 year after surgery(RR=0.852, 95% CI, 0.727-0.998; P=0.047). UCHA showed a shorter operative duration(WMD=8.739, 95% CI, 6.354-11.124; P<0.0001).ConclusionsThis meta-analysis demonstrates that CHA has better hip function, lower rates of refracture, subsidence or loosening, revision, pressure ulcer, pain and one-year mortality than UCHA, while UCHA has shorter operative duration.


Author(s):  
Carolina Beatriz Cunha Prado ◽  
Elaine Alves Silva Machado ◽  
Karina Dal Sasso Mendes ◽  
Renata Cristina de Campos Pereira Silveira ◽  
Cristina Maria Galvão

Objective: to evaluate evidence on effectiveness support surfaces for pressure injury prevention in the intraoperative period. Method: systematic review. The search for primary studies was conducted in seven databases. The sample consisted of 10 studies. The synthesis of the results was carried out descriptively and through meta-analysis. Results: when comparing low-tech support surfaces with regular care (standard surgical table mattress), the meta-analysis showed that there is no statistically significant difference between the investigated interventions (Relative Risk = 0.88; 95%CI: 0.30-2.39). The Higgins inconsistency test indicated considerable heterogeneity between studies (I2 = 83%). The assessment of the certainty of the evidence was very low. When comparing high-tech and low-tech support surfaces, the meta-analysis showed that there is a statistically significant difference between the interventions studied, with high-tech being the most effective (Relative Risk = 0.17; 95%CI: 0.05-0.53). Heterogeneity can be classified as not important (I2 = 0%). The assessment of certainty of evidence was moderate. Conclusion: the use of high-tech support surfaces is an effective measure to prevent pressure injuries in the intraoperative period.


Author(s):  
Seyed Mohammad Mousavi ◽  
Alireza Milajerdi ◽  
Somaye Fatahi ◽  
Jamal Rahmani ◽  
Meysam Zarezadeh ◽  
...  

Abstract. The clinical studies regarding the effect of L-arginine in human anthropometry have not been fully consistent, therefore, we carried out a systematic review and meta-analysis of randomized clinical trials in order to precisely evaluate and quantify the efficacy of L-arginine on weight, waist circumference, and BMI. We searched online databases including PubMed, SCOPUS, and Google Scholar for relevant articles up to September 2017. Eligible articles were reviewed by two independent investigators. Mean differences of the outcomes were used for calculation of weighted mean difference (WMD) derived from the random-effects model. Statistical heterogeneity between studies was examined using Cochran’s Q-test and I 2 index. Funnel plot and Egger’s tests were performed to assess the publication bias. In our initial search, we found 1598 publications, of which 8 RCTs (9 treatment arms) were included. The results of the meta-analysis displayed a significant reduction in WC following L-arginine supplementation (WMD: −2.97 cm; 95% CI: −4.75 to −1.18, P = 0.001). However, L-arginine intervention had not elicited a significant effect on BMI (WMD: −0.51 kg/m2; 95% CI: −1.11 to .08, P = 0.09) and body weight (WMD: −0.57 kg; 95% CI: −1.77 to 0.61, P = 0.34). Subgroup analyses displayed that longer-term interventions (≥8 weeks) had a positive effect on body weight and using < 8 g/day L-arginine with longer duration (≥8 weeks) could significantly decrease BMI. In conclusion, this meta-analysis result suggested L-arginine supplementation could reduce waist circumference without any significant effect on body weight and body mass index.


2021 ◽  
Vol 9 (3) ◽  
Author(s):  
Shahla Rezaei ◽  
Maryam Gholamalizadeh ◽  
Reza Tabrizi ◽  
Peyman Nowrouzi‐Sohrabi ◽  
Samira Rastgoo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document